CoChat

A Novel Artificial MicroRNA Expressing AAV Vector for Phospholamban Silencing in Cardiomyocytes Improves Ca2+ Uptake into the Sarcoplasmic Reticulum

Größl, Tobias, Hammer, Elke, Bien-Möller, Sandra, Geisler, Anja, Pinkert, Sandra, Röger, Carsten, Poller, Wolfgang, Kurreck, Jens, Völker, Uwe, Vetter, Roland, Fechner, Henry · 2014 · PLoS ONE
Cited by 19

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0092188

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Research works printed but not linked: 53

  1. JS Hulot, 2012, Sarcoplasmic reticulum and calcium cycling targeting by gene therapy, Gene Ther, 19, 596, 10.1038/gt.2012.34 · DOI
  2. AM Lompre, 2010, Ca2+ cycling and new therapeutic approaches for heart failure, Circulation, 121, 822, 10.1161/CIRCULATIONAHA.109.890954 · DOI
  3. L Hadri, 2011, Calcium cycling proteins and their association with heart failure, Clin Pharmacol Ther, 90, 620, 10.1038/clpt.2011.161 · DOI
  4. Y Kawase, 2011, Rescuing the failing heart by targeted gene transfer, J Am Coll Cardiol, 57, 1169, 10.1016/j.jacc.2010.11.023 · DOI
  5. Y Kawase, 2008, Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure, J Am Coll Cardiol, 51, 1112, 10.1016/j.jacc.2007.12.014 · DOI · Paper page
  6. Y Iwanaga, 2004, Chronic phospholamban inhibition prevents progressive cardiac dysfunction and pathological remodeling after infarction in rats, J Clin Invest, 113, 727, 10.1172/JCI18716 · DOI · Paper page
  7. T Dieterle, 2005, Gene transfer of a phospholamban-targeted antibody improves calcium handling and cardiac function in heart failure, Cardiovasc Res, 67, 678, 10.1016/j.cardiores.2005.04.029 · DOI
  8. HS Zhang, 2012, A designed zinc-finger transcriptional repressor of phospholamban improves function of the failing heart, Mol Ther, 20, 1508, 10.1038/mt.2012.80 · DOI
  9. A Watanabe, 2004, Phospholamban ablation by RNA interference increases Ca2+ uptake into rat cardiac myocyte sarcoplasmic reticulum, J Mol Cell Cardiol, 37, 691, 10.1016/j.yjmcc.2004.06.009 · doi:10.1016/j.yjmcc.2004.06.009
  10. H Fechner, 2007, Highly efficient and specific modulation of cardiac calcium homeostasis by adenovector-derived short hairpin RNA targeting phospholamban, Gene Ther, 14, 211, 10.1038/sj.gt.3302872 · DOI
  11. L Suckau, 2009, Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy, Circulation, 119, 1241, 10.1161/CIRCULATIONAHA.108.783852 · DOI · Paper page
  12. LM Andino, 2008, AAV-mediated knockdown of phospholamban leads to improved contractility and calcium handling in cardiomyocytes, J Gene Med, 10, 132, 10.1002/jgm.1131 · DOI
  13. LT Bish, 2011, Cardiac gene transfer of short hairpin RNA directed against phospholamban effectively knocks down gene expression but causes cellular toxicity in canines, Hum Gene Ther, 22, 969, 10.1089/hum.2011.035 · DOI
  14. SM Elbashir, 2001, RNA interference is mediated by 21- and 22-nucleotide RNAs, Genes Dev, 15, 188, 10.1101/gad.862301 · DOI · Paper page
  15. YS Lee, 2004, Distinct roles for Drosophila Dicer-1 and Dicer-2 in the siRNA/miRNA silencing pathways, Cell, 117, 69, 10.1016/S0092-8674(04)00261-2 · DOI · Paper page
  16. H Fechner, 2011, Pharmacological and biological antiviral therapeutics for cardiac coxsackievirus infections, Molecules, 16, 8475, 10.3390/molecules16108475 · DOI
  17. J Kurreck, 2009, RNA interference: from basic research to therapeutic applications, Angew Chem Int Ed Engl, 48, 1378, 10.1002/anie.200802092 · DOI · Paper page
  18. TR Brummelkamp, 2002, A system for stable expression of short interfering RNAs in mammalian cells, Science, 296, 550, 10.1126/science.1068999 · DOI · Paper page
  19. Z Huang, 2012, Low-molecular weight chitosan/vascular endothelial growth factor short hairpin RNA for the treatment of hepatocellular carcinoma, Life Sci, 91, 1207, 10.1016/j.lfs.2012.09.015 · DOI
  20. AJ Bridge, 2003, Induction of an interferon response by RNAi vectors in mammalian cells, Nat Genet, 34, 263, 10.1038/ng1173 · DOI · Paper page
  21. TH Hutson, 2012, Lentiviral vectors encoding short hairpin RNAs efficiently transduce and knockdown LINGO-1 but induce an interferon response and cytotoxicity in central nervous system neurones, J Gene Med, 14, 299, 10.1002/jgm.2626 · DOI
  22. R Kenworthy, 2009, Short-hairpin RNAs delivered by lentiviral vector transduction trigger RIG-I-mediated IFN activation, Nucleic Acids Res, 37, 6587, 10.1093/nar/gkp714 · DOI
  23. S Singh, 2011, Subcellular fate and off-target effects of siRNA, shRNA, and miRNA, Pharm Res, 28, 2996, 10.1007/s11095-011-0608-1 · DOI · Paper page
  24. F Borel, 2011, In vivo knock-down of multidrug resistance transporters ABCC1 and ABCC2 by AAV-delivered shRNAs and by artificial miRNAs, J RNAi Gene Silencing, 7, 434
  25. JL McBride, 2008, Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi, Proc Natl Acad Sci U S A, 105, 5868, 10.1073/pnas.0801775105 · DOI · Paper page
  26. RL Boudreau, 2009, Artificial microRNAs as siRNA shuttles: improved safety as compared to shRNAs in vitro and in vivo, Mol Ther, 17, 169, 10.1038/mt.2008.231 · DOI · Paper page
  27. Y Zeng, 2002, Both natural and designed micro RNAs can inhibit the expression of cognate mRNAs when expressed in human cells, Mol Cell, 9, 1327, 10.1016/S1097-2765(02)00541-5 · DOI · Paper page
  28. RA Dickins, 2005, Probing tumor phenotypes using stable and regulated synthetic microRNA precursors, Nat Genet, 37, 1289, 10.1038/ng1651 · DOI · Paper page
  29. S Xiao, 2011, Inhibition of highly pathogenic PRRSV replication in MARC-145 cells by artificial microRNAs, Virol J, 8, 491, 10.1186/1743-422X-8-491 · DOI
  30. KH Chung, 2006, Polycistronic RNA polymerase II expression vectors for RNA interference based on BIC/miR-155, Nucleic Acids Res, 34, e53, 10.1093/nar/gkl143 · DOI · Paper page
  31. AM Denli, 2004, Processing of primary microRNAs by the Microprocessor complex, Nature, 432, 231, 10.1038/nature03049 · DOI · Paper page
  32. Z Shan, 2009, An efficient method to enhance gene silencing by using precursor microRNA designed small hairpin RNAs, Mol Biol Rep, 36, 1483, 10.1007/s11033-008-9339-8 · DOI
  33. D Boden, 2004, Enhanced gene silencing of HIV-1 specific siRNA using microRNA designed hairpins, Nucleic Acids Res, 32, 1154, 10.1093/nar/gkh278 · DOI · Paper page
  34. Maczuga P, Lubelski J, van Logtenstein R, Borel F, Blits B, et al. (2012) Embedding siRNA sequences targeting Apolipoprotein B100 in shRNA and miRNA scaffolds results in differential processing and in vivo efficacy. Mol Ther. · DOI
  35. RL Boudreau, 2008, Minimizing variables among hairpin-based RNAi vectors reveals the potency of shRNAs, RNA, 14, 1834, 10.1261/rna.1062908 · DOI · Paper page
  36. R Vetter, 1998, Influence of different culture conditions on sarcoplasmic reticular calcium transport in isolated neonatal rat cardiomyocytes, Mol Cell Biochem, 188, 177, 10.1023/A:1006850724830 · DOI
  37. OJ Muller, 2008, Augmentation of AAV-mediated cardiac gene transfer after systemic administration in adult rats, Gene Ther, 15, 1558, 10.1038/gt.2008.111 · DOI
  38. S Pinkert, 2009, Prevention of cardiac dysfunction in acute coxsackievirus B3 cardiomyopathy by inducible expression of a soluble coxsackievirus-adenovirus receptor, Circulation, 120, 2358, 10.1161/CIRCULATIONAHA.108.845339 · DOI · Paper page
  39. H Fechner, 2007, Coxsackievirus B3 and adenovirus infections of cardiac cells are efficiently inhibited by vector-mediated RNA interference targeting their common receptor, Gene Ther, 14, 960, 10.1038/sj.gt.3302948 · DOI
  40. A Geisler, 2011, microRNA122-regulated transgene expression increases specificity of cardiac gene transfer upon intravenous delivery of AAV9 vectors, Gene Ther, 18, 199, 10.1038/gt.2010.141 · DOI
  41. I Sipo, 2007, Differential internalization and nuclear uncoating of self-complementary adeno-associated virus pseudotype vectors as determinants of cardiac cell transduction, Gene Ther, 14, 1319, 10.1038/sj.gt.3302987 · DOI
  42. E Varkonyi-Gasic, 2010, qRT-PCR of Small RNAs, Methods Mol Biol, 631, 109, 10.1007/978-1-60761-646-7_10 · DOI
  43. J Cernohorsky, 1998, Thyroid control of sarcolemmal Na+/Ca2+ exchanger and SR Ca2+-ATPase in developing rat heart, Am J Physiol, 275, H264
  44. A Keller, 2002, Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search, Anal Chem, 74, 5383, 10.1021/ac025747h · DOI · Paper page
  45. E Hammer, 2011, Characterization of the human myocardial proteome in inflammatory dilated cardiomyopathy by label-free quantitative shotgun proteomics of heart biopsies, J Proteome Res, 10, 2161, 10.1021/pr1008042 · DOI
  46. OJ Muller, 2006, Improved cardiac gene transfer by transcriptional and transductional targeting of adeno-associated viral vectors, Cardiovasc Res, 70, 70, 10.1016/j.cardiores.2005.12.017 · DOI · Paper page
  47. JC Giering, 2008, Expression of shRNA from a tissue-specific pol II promoter is an effective and safe RNAi therapeutic, Mol Ther, 16, 1630, 10.1038/mt.2008.144 · DOI · Paper page
  48. P Maczuga, 2012, Optimization and comparison of knockdown efficacy between polymerase II expressed shRNA and artificial miRNA targeting luciferase and Apolipoprotein B100, BMC Biotechnol, 12, 42, 10.1186/1472-6750-12-42 · DOI
  49. K Haghighi, 2003, Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human, J Clin Invest, 111, 869, 10.1172/JCI17892 · DOI · Paper page
  50. KJ Shin, 2006, A single lentiviral vector platform for microRNA-based conditional RNA interference and coordinated transgene expression, Proc Natl Acad Sci U S A, 103, 13759, 10.1073/pnas.0606179103 · DOI · Paper page
  51. SD Selcuklu, 2009, miR-21 as a key regulator of oncogenic processes, Biochem Soc Trans, 37, 918, 10.1042/BST0370918 · DOI · Paper page
  52. Y Cheng, 2010, MicroRNA-21 in cardiovascular disease, J Cardiovasc Transl Res, 3, 251, 10.1007/s12265-010-9169-7 · DOI · Paper page
  53. T Thum, 2008, MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts, Nature, 456, 980, 10.1038/nature07511 · DOI · Paper page

Cited by

See all 19

Metadata

Authors
Größl, T., Hammer, E., Bien-Möller, S., Geisler, A., Pinkert, S., Röger, C., Poller, W., Kurreck, J., Völker, U., Vetter, R., & Fechner, H.
Venue
PLoS ONE
Published
2014-03-26
Volume
9
Issue
3
Pages
e92188
ISSN
1932-6203
Cited by
19
References
5
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Novel Artificial MicroRNA Expressing AAV Vector for Phospholamban Silencing in Cardiomyocytes Improves Ca2+ Uptake into the Sarcoplasmic Reticulum. https://app.cochat.ai/papers/10.1371/journal.pone.0092188
The paper
Größl, T., Hammer, E., Bien-Möller, S., Geisler, A., Pinkert, S., Röger, C., Poller, W., Kurreck, J., Völker, U., Vetter, R., & Fechner, H. (2014). A Novel Artificial MicroRNA Expressing AAV Vector for Phospholamban Silencing in Cardiomyocytes Improves Ca2+ Uptake into the Sarcoplasmic Reticulum. PLoS ONE. https://doi.org/10.1371/journal.pone.0092188

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.